Early stage oncology new product development is a rather strange beast at times.

On the one hand is the tendency of small biotechs to over inflate their datasets or cherry pick subsets to try and make them more impressive than they really are…

And on the other is a real challenge in trying to pick out a clear signal from the noise.

In our latest review there are some cautionary examples from both extremes, as well as some intriguing novel targets to look at.

Some of these require zooming out for a better big picture perspective, while others deserve to be put under the microscope more critically.

These latest examples span the gamut from bispecifics and CAR-T cells to degraders in a range of hematologic malignancies and solid tumour types…

To learn more from our latest oncology review and get a heads up on key cancer research insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by